Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Idorsia
Biotech
Idorsia bags $350M upfront from Viatris for 2 late-phase assets
Weeks from the end of its cash runway, Idorsia has secured $350 million upfront from Viatris in exchange for the global rights to two phase 3 assets.
Nick Paul Taylor
Feb 28, 2024 7:56am
Idorsia lays off 300 staff after previewing cost cuts in July
Oct 24, 2023 10:30am
J&J hands back $230M blood pressure drug with approval in sight
Sep 6, 2023 6:20am
500 roles threatened as Idorsia tries to reduce cash burn by 50%
Jul 21, 2023 5:13am
Neurocrine axes essential tremor program on phase 2 data
Aug 5, 2022 4:53am
J&J's $230M blood pressure bet hits phase 3 endpoint
May 23, 2022 8:57am
